Skip to main content
Oncotarget logoLink to Oncotarget
. 2021 Oct 12;12(21):2232–2233. doi: 10.18632/oncotarget.28096

Correction: Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer

Takahito Sugase 1,2,3, Tsuyoshi Takahashi 1,, Satoshi Serada 2, Minoru Fujimoto 2, Tomoharu Ohkawara 2, Kosuke Hiramatsu 1,2,3, Masahiro Koh 1, Yurina Saito 1, Koji Tanaka 1, Yasuhiro Miyazaki 1, Tomoki Makino 1, Yukinori Kurokawa 1, Makoto Yamasaki 1, Kiyokazu Nakajima 1, Kazuhiro Hanazaki 3, Masaki Mori 1, Yuichiro Doki 1, Tetsuji Naka 2,
PMCID: PMC8522840  PMID: 34676057

This article has been corrected: In Figure 1C, the image in row 2, column 2 is an accidental duplicate of the image in row 4, column 2. The corrected Figure 1C, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Figure 1. Immunohistochemical (IHC) staining for lipolysis-stimulated lipoprotein receptor (LSR) in gastric cancer (GC) patient samples.

Figure 1

(C) Primary GC, lymph node metastasis, and distant metastasis (peritoneum and liver) of 7 patients with GC.

Original article: Oncotarget. 2018; 9:32917–32928. 32917-32928. https://doi.org/10.18632/oncotarget.25952


Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES